Amarin Corporation plc

Welcome to Ameren Corporation's conference call to discuss its fourth quarter and full year 2020 financial results and operational updates. This conference call is being recorded today, February 25th, 2021. I would like to turn the conference call over to Alina Dabrovna, Associate Manager of Investor Relations at Ameren.

Thank you, Operator, and thank you to everyone for joining our fourth quarter and full year 2020 results Before we begin, let me turn to our forward-looking statement.

Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to, our current expectations regarding our commercial and financial performance, including levels of ACIPA prescriptions, ACIPA product and licensing revenues, costs, gross margin, and other commercial metrics. Our current plans and expectations regarding spending, including expenditures for the promotion of the SEPA and for purchases of additional supply of the SEPA. Our current expectations regarding the adequacy of our financial resources. Our current plans and expectations for product revenue growth, sales force productivity, and product promotion in light of COVID-19. and the potential for adding attention to cardiovascular risk reduction drugs like the SIPA as a result of COVID-19. Our current plans and expectations related to patent litigation and expectations related to the potential launch of generic versions of the SIPA by generic companies and by ourselves. Our current expectations on the substance and timing of the SIPA regulatory reviews outside of the United States. Our current plans and expectations regarding the timing, scope, and success of international expansion, including expectations regarding our ability to launch the SCEPA in Europe and our expectations in China for clinical trial results and potential to bridge reducing results in labeling and promotion of the SCEPA through our partner in China. Our current plans and expectations regarding the SCEPA exclusivity outside of the United States, including Europe and China. Our current plans for commercial expansion in the United States with the entry of current and potential future generic competition. And our current plans and expectations regarding the clinical study of the SEPA related to COVID-19. These statements are based on information available to us today, February 25, 2021. We may not actually achieve our goals, carry out our plans or intentions, or meet the expectations disclosed in our forward-looking statements. actual results and events could differ materially. So, you should not place undue reliance on these statements. We assume no obligation to update these statements if circumstances change. Our forward-looking statements do not reflect the potential impact of significant transactions we may enter into, such as mergers, acquisitions, dispositions, joint ventures, or any material agreements we may enter into, amend, or terminate. For additional information concerning the factors that could cause actual results to differ materially, please see the risk factor section of our annual report on Form 10-K for the year ended December 31, 2020, which has been filed with the SEC and is available through the investor relations section of our website at www.amarincorp.com. We encourage everyone to read this document. This call is intended for investors. in Ameren, and it is not intended to promote the use of a SEPA outside its approved indication. An archive of this call will be posted on Ameren's website within the investor relations section. Making prepared remarks on today's call will be John Farrell, President and Chief Executive Officer, and Michael Kalb, Chief Financial Officer. After prepared remarks, we will open the call to your questions. I remind you that multiple audiences typically listen to calls of this nature, including existing investors, potential new investors, employees, current and potential collaborators, and current and potential competitors. As always, in this call, we will attempt to provide constructive information without compromising our competitive and strategic positioning. I now turn the call over to John Farrow, President and Chief Executive Officer of Ameren.